Chronic pain represents a global public health crisis. Opioid analgesics are limited by respiratory depression, addiction, tolerance, and hyperalgesia, driving demand for mechanism-based non-opioid treatments [1]. Ziconotide is a first-in-class intrathecal analgesic that selectively blocks Ca_V2.2 channels on presynaptic nociceptor terminals, inhibiting calcium influx and neurotransmitter release. It produces potent analgesia across acute, inflammatory, and neuropathic pain without abuse liability [2,3]. However, clinical use is restricted by a steep dose-response curve, neurological side effects (dizziness, ataxia, nystagmus), and invasive delivery [4,5]. Combination strategies that potentiate ziconotide at lower doses could greatly expand its utility, but their translational feasibility remains underexplored [6].

Neuropeptide FF (NPFF) and related peptides (NPVF, dNPA) act on two G_i/o-coupled G-protein-coupled receptors (GPCRs), NPFF1 and NPFF2, which are densely expressed in spinal somatosensory pathways [7–9]. NPFF receptors modulate nociception, opioid tolerance, and withdrawal, and inhibit Ca_V2.2 in vitro via G_βγ signaling [10,11]. Until recently, however, there was a lack of in vivo evidence linking NPFF signaling to Ca_V2.2-mediated analgesia [12].Jin et al. used mouse thermal (tail-flick) and visceral (acetic acid writhing) pain models to assess the interaction. We found that intrathecal NPFF, NPVF, or dNPA dose-dependently enhanced ziconotide analgesia without affecting baseline nociception. This effect was abolished by the NPFF antagonist RF9 but not by the opioid antagonist naloxone, confirming opioid independence. Notably, 8-day co-administration did not induce tolerance [12].

These findings demonstrate that the NPFF system acts as an endogenous functional modulator that potentiates ziconotide-induced analgesia, thereby supporting the potential of ziconotide?NPFF combination therapy. However, the study was limited to acute pain models in male mice; whether similar potentiation occurs in chronic pain states or both sexes remains unknown. Additionally, while NPFF agonists show promise, their safety profile-particularly regarding off-target effects on autonomic or neuroendocrine functions-requires systematic evaluation prior to clinical translation.

This commentary expands these findings by: (1) Contextualizing NPFF-Ca_V2.2 crosstalk within modern GPCR-ion channel signaling; (2) Dissecting NPFF1/NPFF2 subtype roles in spinal analgesia; (3) Evaluating translational potential for intrathecal therapy; (4) Highlighting key unresolved mechanistic and clinical questions, including the pharmacokinetic feasibility of intrathecal NPFF delivery (e.g., cerebrospinal fluid stability, compatibility with implantable pumps) and the need for chronic pain and sex specific preclinical validation. Future first-in-human trials should prioritize dose- escalation safety studies with rigorous neurological and autonomic monitoring. Overcoming the blood-brain barrier impermeability of peptides remains a major translational barrier for systemic delivery, though intrathecal administration bypasses this issue.

Ca_V2.2 channels are key regulators of nociceptive neurotransmitter release [2,13]. Ziconotide binds the extracellular pore and causes voltage-independent, use-dependent block [2,3]. In contrast, G_i/o-coupled GPCRs (including NPFF receptors) inhibit Ca_V2.2 via membrane-delimited G_βγ signaling, stabilizing closed states and reducing open probability without pore occlusion [11,14,15]. These distinct mechanisms create a strong basis for functional synergy [12,14].

Structural and functional studies show that G_βγ interacts with the Ca_V2.2 intracellular I-II loop and C-terminus of Ca_V2.2, thereby reducing gating efficacy [11,14]. This preferentially suppresses release during high neuronal activity (pathological pain) while sparing basal transmission [14,16]. NPFF receptors do not bind Ca_V2.2 directly but modulate channel activity via G_i/o signaling, forming a functional complex at presynaptic active zones [12,17]. However, most evidence for direct G_β-Ca_V2.2 interactions comes from heterologous expression systems; whether native spinal presynaptic terminals employ identical molecular mechanisms remains less directly validated.

A schematic representation of the proposed NPFF-Ca_V2.2 signaling synergy with ziconotide is provided in Figure 1.

Figure 1. Schematic of NPFF-CaV2.2 crosstalk and synergy with ziconotide at spinal presynaptic nociceptor terminals.

NPFF2 receptors (predominant in spinal cord) activate G_i/o proteins, releasing G_βγ subunits that bind Ca_V2.2 channels to reduce open probability. Ziconotide blocks the channel pore. These distinct inhibitory mechanisms act synergistically to suppress calcium influx and neurotransmitter release. NPFF1 receptors (mainly supraspinal) are not shown here. Jin et al. used mouse thermal (tail-flick) and visceral (acetic acid writhing) pain models to assess the interaction. They found that ziconotide analgesia is independent of opioid or NPFF tone: naloxone and RF9 did not alter the effect of ziconotide given alone. However, NPFF receptor activation shifted the ziconotide dose-response leftward, enhancing analgesia at submaximal doses. This pattern reflects functional potentiation via downstream signaling, supporting clinically meaningful dose sparing [12].

In the study by Jin et al., both NPFF1-preferring (NPVF) and NPFF2-selective (dNPA) agonists produced similar potentiation. This finding suggests that either subtype can drive sufficient Ca_V2.2 modulation, or alternatively, that both receptors couple to overlapping G_i/o pathways [7,8,12]. However, these interpretations remain speculative, because subtype-selective antagonists or genetic knockdown were not used. Therefore, future work with subtype-selective tools will be required to clarify the dominant receptor contributions in vivo.

NPFF1 receptors are concentrated in hypothalamic neuroendocrine regions, while NPFF2 receptors predominate in the spinal dorsal horn, thalamus, and brainstem-areas critical for nociception [7–9]. This distribution implies that spinal analgesic effects are likely NPFF2-driven, with NPFF1 modulating supraspinal affective or neuroendocrine pain components [7,9]. However, direct functional evidence for this subtype specialization in the spinal cord remains limited, as most data are derived from receptor localization studies rather than in vivo functional dissection.

In the study by Jin et al., NPVF and dNPA enhanced ziconotide analgesia similarly at equimolar doses. Possible explanations: (1) Overlapping signaling: both receptors efficiently couple to G_i/o-G_βγ-mediated Ca_V2.2 inhibition [7,10,14]. (2) Co-expression: spinal circuits co-express both subtypes, so either activates a common pool [7,8]. (3) Ligand cross-reactivity: partial non-selectivity masks strict subtype dependence [7,8]. Importantly, because the study did not employ subtype-selective antagonists or genetic knockdown, these interpretations remain speculative.

In visceral pain, dNPA tended to be more potent, consistent with spinal NPFF2 upregulation in inflammatory and neuropathic states [9,12]. This observation suggests that NPFF2-selective agonists may be superior in pathological pain, although this inference requires confirmation in additional pain models and with selective pharmacological tools.

Ca_V2.2 and NPFF receptors are expressed on primary afferent terminals and spinal interneurons. Future work using conditional knockout, electrophysiology, and calcium imaging will help define cell-type-specific modulation. Such studies should also clarify whether NPFF enhances ziconotide’s inhibition of primary afferent release or alternatively engages pain-gating inhibitory circuits [3,16].

Ziconotide’s clinical potential is limited by dose-related neurological side effects and intrathecal delivery [4]. The findings of Jin et al. strongly support intrathecal co-administration of ziconotide with stable NPFF agonists. This combinatorial approach avoids the limitations of single-drug therapy, providing a safe and tolerable option for intrathecal pain management. This study is preliminary, and the long-term safety and clinical application of the combined strategy need further verification through subsequent in vivo experiments and clinical trials.

Dose reduction and mitigation of neurological side effects

Ziconotide’s therapeutic index is narrow because analgesic and neurotoxic doses are closely spaced. Side effects stem from supraspinal Ca_V2.2 blockade in cerebellar and vestibular pathways [4]. Based on existing experimental evidence, NPFF-based combinatorial strategies can enhance ziconotide’s analgesic efficacy. This may allow a reduction in ziconotide dosage, thereby mitigating its neurological side effects. Such an approach could inform the development of novel combinatorial analgesic strategies for intrathecal delivery. However, the safety profile of chronic intrathecal NPFF agonists themselves remains unexplored; potential adverse effects on autonomic, endocrine, or motor functions require systematic evaluation before clinical translation. Furthermore, intrathecal co-administration introduces pharmacokinetic uncertainties, including peptide stability in cerebrospinal fluid, compatibility with implantable pumps, and potential for altered ziconotide clearance.

Opioid independence

A key advantage is strict opioid independence. Naloxone did not block NPFF-mediated potentiation, confirming analgesia occurs without opioid receptor activation [12,18]. This feature is valuable for patients with opioid intolerance, addiction risk, or opioid-induced hyperalgesia, and may reduce reliance on systemic adjuvants that carry their own side effects [1,6,18].

Tolerance resistance

Ziconotide monotherapy exhibits no tolerance [4]. Jin et al. showed no analgesic tolerance after 8 days of ziconotide monotherapy or ziconotide-NPFF co-administration. The study suggests that NPFF sustains ziconotide’s inhibitory efficacy toward Ca_V2.2 channels without inducing compensatory adaptive remodeling. It remains speculative whether NPFF preserves this favorable profile by reinforcing ziconotide’s target engagement, possibly through modulation of Ca_V2.2-associated signaling pathways [1,12]. Regardless, the combination appears promising for chronic intrathecal infusion in refractory pain, pending longer-term safety studies.

Broadened pain indications

Ziconotide efficacy varies across pain etiologies [4]. Because NPFF receptors are upregulated in neuropathic and inflammatory pain, potentiation may be stronger in pathological states [9]. Jin et al.’s visceral pain model showed robust enhancement, supporting use in abdominal, pelvic, and visceral pain often poorly managed by conventional analgesics. Future studies should test efficacy in nerve injury, diabetic neuropathy, and spinal cord injury models, and should include both sexes to assess potential sex-dependent differences in NPFF-Ca_V2.2 signaling.

Despite major advances, key questions remain:

Subtype-selective pharmacology

Highly selective NPFF1 and NPFF2 antagonists for in vivo use are lacking [7,8]. Such tools are needed to definitively assign subtype contributions to ziconotide potentiation and to determine whether single-subtype targeting suffices or dual targeting is optimal. In the absence of these tools, the relative contributions of NPFF1 versus NPFF2 subtypes remain speculative.

Molecular crosstalk mechanisms

While G_i/o-G_βγ signaling is central, downstream effectors are poorly defined. For example, it remains unknown whether NPFF alter Ca_V2.2 trafficking, gating kinetics, or phosphorylation state. Live-cell imaging, proteomics, and neuronal electrophysiology will define the molecular links between NPFF receptors and enhanced ziconotide inhibition.  However, most current evidence is derived from heterologous expression systems; validation in native spinal presynaptic terminals is still needed.

Clinical safety and pharmacokinetics

Intrathecal polypharmacy necessitates rigorous evaluation of pharmacokinetic interactions and synergistic neurological side effects. A critical unresolved question is whether NPFF agonists may modify ziconotide clearance or or its distribution in cerebrospinal fluid and spinal cord. Additionally, the feasibility of chronic co-administration via implantable intrathecal pumps (including issues of peptide stability, aggregation, and compatibility) requires preclinical assessment. These are key determinants for safe intrathecal combination therapy and warrant preliminary nonclinical pharmacokinetic and safety studies, followed by early-phase clinical trials to reduce translational risks.

Jin et al. establish a novel opioid-independent analgesic axis where spinal NPFF receptor activation enhances Ca_V2.2-mediated ziconotide analgesia. This work bridges basic neuropharmacology and clinical pain care, offering a strategy to overcome limitations of current non-opioid therapies. By enabling ziconotide dose reduction, preserving long-term efficacy without apparent tolerance, and acting across pain modalities, ziconotide-NPFF combination therapy represents a promising paradigm for intrathecal analgesia.

Future investment in subtype-selective ligands, mechanistic dissection of GPCR-ion channel crosstalk, and rigorous translational development will be critical. First-in-human trials should prioritize dose-escalation safety studies with close monitoring for neurological, autonomic, or endocrine adverse events. Major translational barriers include the lack of long-term safety data, uncertainty about optimal dosing regimens, and the need for specialized intrathecal delivery infrastructure. Overcoming these hurdles will determine whether this endogenous modulatory pathway can be successfully translated into clinical practice. The NPFF-Ca_V2.2 pathway demonstrates how endogenous neuromodulatory systems can optimize existing therapeutics, providing a rational framework for next-generation mechanism-based non-opioid pain treatments.

The authors have no conflicts of interest to declare.

This work was supported by the project (XJ202510634215).